CONDOR diagnostic evaluation platform
CONDOR provides a single national route to evaluate new diagnostic tests for COVID-19.
The CONDOR platform is accelerating how quickly promising COVID-19 diagnostics make it into real-world use. It is evaluating new COVID-19 diagnostics in the settings they will be used, such as in GP surgeries, care homes or hospitals, as well as their performance in laboratory settings.
The CONDOR platform consists of six different workstreams – three clinical evaluation studies, and three cross cutting studies.
Clinical evaluation studies:
- FALCON-C19: The FALCON-C19 study covers hospital emergency departments, inpatient areas, e.g. COVID wards, acute medical units and critical care, and 'Hospital at Home Services'.
- CONDOR-CH: The CONDOR-CH study is looking at rapid testing specifically in care home settings.
- RAPTOR-C19 is focussed on community settings, such as GP surgeries and COVID-19 testing centres
Cross cutting studies:
- Care Pathway Analysis: "Care pathway mapping” studies will identify where new technologies could have the most impact on patient health during the different phases of the pandemic.
- Human Factors analysis: Analysing the interaction between people and technologies in real-world healthcare.
- Analytical performance: Evaluating which tests should be trialled in the different clinical settings and putting the right ones forward into our clinical studies.
Co-led between the University of Oxford with Manchester University’s Diagnostic and Technology Accelerator (DiTA), project partners include the University of Nottingham, NIHR MedTech and In Vitro Diagnostic Co-operatives based in Oxford, Leeds, London and Newcastle, AHSN North East and North Cumbria, and Yorkshire and Humber AHSN.
Oxford co-leads: Associate Professor Gail Hayward (CONDOR), Dr Brian Nicholson (RAPTOR C-19)
Research Groups: NIHR Community Healthcare MedTech and In Vitro Diagnostics Co-operative, Cancer Research Group
Funding: UKRI, NIHR, Asthma UK, British Lung Foundation.